Anne Wojiciki

Anne Wojcicki

Democratizing DNA

Led by CEO Wojcicki, 23andMe gives users insights into their genetic makeup with a saliva sample. In March, the company became the first to offer an FDA-approved home genetic test for cancer risk; for $199, it provides a limited look into increased risks for breast, ovarian and prostate cancers. And in July, GlaxoSmithKline became 23andMe’s latest pharma partner, leveraging users’ anonymous genetic data to develop drugs. —Mandy Oaklander
